Pfizer Corporation

Icagen, Inc.

David James Rawson

Nigel Alan Swain

Robert Ian Storer

Graham Nigel Maw

Alan Daniel Brown

Brian Edward Marron

Kevin Neil Dack

David Simon Millan

Roger P Dickinson

Paul Anthony Stupple

Kim James

Christopher William West

Russell Andrew Lewthwaite

Christopher John Markworth

Shulan Zhou

Andrew Simon Bell

Serge Beaudoin

Julian Blagg

Michael Christopher Laufersweiler

Steven Michael Reister

Marcel John De Groot

Kosuke Sasaki

Charlotte Moira Norfor Allerton

Christopher Gordon Barber

Thomas Ryckmans

Ian Roger Marsh

Lisa Rosemary Thompson

Nunzio Sciammetta

Manuel Perez Pacheco

Laurence Edward Burgess

James P Rizzi

Andrew Douglas Baxter

Mark Edward Bunnage

Justin Stephen Bryans

John Paul Mathias

Anthony Wood

Simon John Mantell

Charlotte Alice Louise Lane

Mark Ian Kemp

Keith Michael DeVries

David Ellis

Patrick Stephen Johnson

Stephen Derek Albert Street

Philip Charles Levett

Albert Shaw Wood

Andrew Michael Derrick

Laurence James Harris

Stephen Challenger

Joanna Teresa Negri

Stephen Martin Denton

Julie Newman

Jacob Bradely Schwarz

Robert Duncan Armour

Yousef Hajikarimian

Manuel Perez-Pacheco

Sandra Dora Newman

Steven Matthieu Gaulier

Benjamin Scott Greener

Shelley Rene Graham

Charlotte Alice Lane

Sebastien Rene Galan

The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Sulfonamide compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to 5 compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): 10 X NH O S O O R1 R2 R5 R4 R3 Het1 (I) or a pharmaceutically acceptable salt thereof, wherein X, Het1, R1, R2, R3, R4 and R5 are as defined in the description. 15 Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Acyl sulfonamide compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Y, Z, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain. 

N-sulfonylbenzamide compounds

The present invention relates to sulfonamide derivatives, of formula (I): or a pharmaceutically acceptable salts thereof, wherein X, Z, R, R, R, R, Rand Rare as defined in the description, and to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. The compounds of formula (I) are Nav1.7 inhibitors useful in the treatment of a wide range of disorders, particularly pain.

Sulfonamide derivatives

The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z, R, R, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Chemical compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R3, R4 and R5 are as defined in the description. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar, X, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes.  These compounds are inhibitors of Nav1.7.

Sulfonamide derivatives as Nav 1.7 inhibitors

The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. 

Therapeutic proline derivatives

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain. 

Pyridine derivatives

The present invention relates to a method of treating pain using a compound of formula wherein R, R, Rand Rare as defined herein. The invention also relates to certain novel derivatives of formula (I).

Amino acid derivatives

Growing community of inventors

Sandwich, United Kingdom

David James Rawson